Stockscreener 앱 받기
41.85
0.57%
-0.24
Merus N V 주식(MRUS)의 최신 뉴스
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewswire
Merus Launches Phase 2 Trial for Novel Cancer Drug Petosemtamab in Advanced Colorectal Cancer - StockTitan
Merus N.V.'s SWOT analysis: antibody innovator's stock faces pivotal year - Investing.com
Franklin Resources Inc. Acquires 150,341 Shares of Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Technical Data - Stock Traders Daily
Lord Abbett & CO. LLC Purchases 328,316 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Janus Henderson Group PLC Has $944,000 Stake in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight - Insider Monkey
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy - Insider Monkey
Merus (NASDAQ:MRUS) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Wellington Management Group LLP Grows Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus’ (MRUS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Citi raises Merus target to $97 on positive trial data By Investing.com - Investing.com South Africa
Citi raises Merus target to $97 on positive trial data - Investing.com
Needham & Company LLC Reaffirms "Buy" Rating for Merus (NASDAQ:MRUS) - MarketBeat
The Manufacturers Life Insurance Company Has $2.56 Million Stock Position in Merus (NASDAQ:MRUS) - Defense World
Positive early data on Merus’ petosemtamab - The Pharma Letter
The Manufacturers Life Insurance Company Sells 11,463 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC - GlobeNewswire Inc.
Zwischenergebnisse der Monotherapie mit Petosemtamab von - GlobeNewswire
US FDA approves Merus' therapy to treat lung, pancreatic cancers - MSN
Merus’ Petosemtamab Monotherapy Interim Data Continues to - GlobeNewswire
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - The Manila Times
Merus's Cancer Drug Shows 36% Response Rate in Head & Neck Cancer Trial, Including Complete Responses - StockTitan
FY2025 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus Scores Its First FDA Approval For Lung Cancer Drug - Benzinga
First for Merus, first for NRG1+ cancers: US FDA approves Bizengri - BioWorld Online
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers - Yahoo Finance
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' - Benzinga
A first for Merus’ Bizengri with FDA nod - The Pharma Letter
Trend Tracker for (MRUS) - Stock Traders Daily
Guggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS) - Defense World
William Blair Has Bearish Forecast for Merus Q3 Earnings - Defense World
US drug body approves Merus' therapy for lung, pancreatic cancer patients - Business Standard
Cramer's Lightning Round: Merus is 'very speculative' - CNBC
Merus Gets FDA Approval for Bizengri Treatment - Marketscreener.com
Merus Announces FDA Approval of BIZENGRI® - GlobeNewswire
Merus Secures FDA Approval for Groundbreaking NRG1+ Cancer Treatment BIZENGRI - StockTitan
Merus’ zenocutuzumab-zbco granted accelerated approval by FDA - TipRanks
Merus price target lowered to $109 from $111 at Guggenheim - Yahoo Finance
Merus's SWOT analysis: biotech stock's potential in antibody therapies By Investing.com - Investing.com South Africa
Merus's SWOT analysis: biotech stock's potential in antibody therapies - Investing.com
Merus shares target cut, buy rating held on PTx deal By Investing.com - Investing.com Canada
Merus shares target cut, buy rating held on PTx deal - Investing.com
HighVista Strategies LLC Reduces Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus's SWOT analysis: innovative antibody stock shows promise amid clinical trials - Investing.com
BMO maintains $95 target on Merus, positive on trial data By Investing.com - Investing.com Canada
Merus licenses cancer drug to Partner Therapeutics for US market By Investing.com - Investing.com Canada
2.88%
2.65%
자본화:
|
볼륨(24시간):